about
Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value.Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case reportNeoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expressionPrognostic significance of osteopontin expression in early-stage non-small-cell lung cancer.Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomasPhosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.Histo-cytological diagnostic accuracy in lung cancer.Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis.Polymorphisms within inflammatory genes and colorectal cancer.CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma.Mutations of Fas (APO-1/CD95) and p53 genes in nonmelanoma skin cancer.Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation.Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors.DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region.Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.Effect of type I interferon(s) on cell viability and apoptosis in primary human thyrocyte cultures.Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study.Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients.Telomerase in intracranial meningiomas.The role of somatostatin in vasogenic meningioma associated brain edema.Meningioma-associated brain oedema: the role of angiogenic factors and pial blood supply.Telomerase activity and hTERT mRNA expression in glial tumors.Management of pleural recurrence after curative resection of thymoma.Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.Modulation of neoangiogenesis in bronchial preneoplastic lesions.Expression of cyclooxygenase-2 and its correlation with vasogenic brain edema in human intracranial meningiomas.Targeting of O6-methylguanine-DNA methyltransferase (MGMT) activity by antimessenger oligonucleotide sensitizes CHO/Mex+ transfected cells to mitozolomide.Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction.CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.Expression of endothelin 1 and its angiogenic role in meningiomas.Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.Tumour necrosis factor-alpha: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer.Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.
P50
Q27824818-AE09B249-5995-4248-A56A-C8FD2B297064Q34152239-25C0B765-C393-4513-B7DD-6B1F330DA9C4Q34346624-2E581DAA-0806-4C23-A319-67507ED5DB38Q34583795-E7A82EB6-8D09-4084-AD8E-60B8FD9DD97EQ35167477-C64A8FE9-322C-4AE5-9497-DFABE81FAD05Q36431673-EEEB6695-A8A0-4E48-B877-9FFC9B4E41CFQ36615218-6FAEFC50-2657-4B7A-8933-A80E36C0FE92Q36617389-806B1FF5-AAF2-4D26-95D3-B54D261D4A67Q36642695-EFAF8E5A-98ED-441D-8087-9BCD70496FBFQ36644123-607A94C2-E367-4319-A2CA-19FEC7E2DC2AQ37457750-9F20BA44-424B-4F73-AD57-0D55400F79A0Q38164052-23AB67C9-E044-4F74-A7B5-E1EDAC67441CQ38428607-DD7F0A69-1D6B-419D-A91F-78A036BF950BQ39066122-8E404A9F-2D5B-4CEA-9A40-1410B44C7871Q42455141-23904C03-0001-4DE6-8E19-E6E8A8E6C37FQ42528131-FB5DF0C6-9708-44CF-9A55-FED7A7761655Q42743383-ECA95DC0-FD3A-4DC8-9B1C-8C0A897ECE1DQ43080122-2475C386-344A-416D-BA02-E3E22249D4C9Q43175897-74D41218-91D8-45F3-B7A6-99624647F278Q43282234-40CDC95C-9491-403D-9EF6-F9419289A1CDQ44721028-44229686-733F-40B5-814D-73CD0BCF1E93Q44813958-E46045B0-E210-4EE6-A37D-F442D4A21DF1Q46743110-E24DF2F8-BBB7-44C8-99AC-CE0EA9F5BF86Q48147697-9026407F-BC9B-4941-891F-FD83F9487072Q48263711-87C35933-E1B8-4033-BE97-D32EF17D4268Q48365305-8F6394B1-C1E9-41D2-A24E-F439E123FD0EQ48548441-8D775E93-8153-4734-BCA1-8C7DB83FF2EFQ50610978-736C2F11-E663-4CCE-AE51-01D3D27DE9AFQ52194096-24037B13-A99B-4BDB-9EBC-02EE8DB9134FQ53422520-A27FD6CF-48B8-4DA2-A706-5DA93AEFAF90Q53457621-2E78BECD-7910-40E5-BC2B-408CA68BA88EQ53458876-1B0FF2B0-84A7-4958-B9AE-40C2E11DFA1EQ53475383-252EF94B-3B40-485B-99A6-C846181F5CCBQ53538681-1A9F5328-B676-480A-BCC1-E5CAB22D0D1AQ53659531-653D84C8-47AD-4B81-A17C-3E46A6E5465BQ53930034-5E2BF11E-12B4-4333-A7ED-7F95E5E8CD4EQ54241216-41E951D4-B3D5-4933-ABC6-AF16AF05E021Q54367113-A14863BA-5DA3-4F0B-919D-A766A29476F9Q54610296-69DA403E-46A2-41EA-9B03-72630DF8FF52Q54618653-7A033EE6-D871-4D08-912E-DD384AF8A45C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laura Boldrini
@ast
Laura Boldrini
@en
Laura Boldrini
@es
Laura Boldrini
@nl
Laura Boldrini
@sl
type
label
Laura Boldrini
@ast
Laura Boldrini
@en
Laura Boldrini
@es
Laura Boldrini
@nl
Laura Boldrini
@sl
prefLabel
Laura Boldrini
@ast
Laura Boldrini
@en
Laura Boldrini
@es
Laura Boldrini
@nl
Laura Boldrini
@sl
P106
P21
P31
P496
0000-0001-5904-3708